Chiesi announced it has secured from UCB rights to zampilimab, a monoclonal antibody being investigated to treat idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Under the agreement, Chiesi acquired global exclusive rights to develop and manufacture the potential antifibrotic therapy, and to market it should it be approved. “We are confident that Chiesi, a company with an established global presence and a focus on the development of novel drug candidates for the treatment of idiopathic pulmonary…

You must be logged in to read/download the full post.